News

Sugammadex Sodium API – CADIFA Approval by ANVISA

We are glad to announce the granting of the first CADIFA ever issued by ANVISA on the 08th of September 2021, regarding the API SUGAMMADEX SODIUM, under the requirements of the Resolution – RDC nº 359/2020. This is a landmark and a moment of great happiness for us that have worked relentlessly in partnership with ANVISA and our clients at the Pharmaceutical Industry to make this achievement come true.

Email us: api@drreddys.com
+91 40 49002253

Contact Us

Please fill in the following form and we'll get back to you shortly.

* I agree and accept the Privacy Policy and Terms of Use of this website.

Email us: api@drreddys.com | +91 40 49002222

Disclaimer

No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.